CAS No. |
111358-88-4 |
中文名称 |
(5S,6S,8R)-6-羟基-6-(羟甲基)-5-甲基-5,6,7,8,14,15-六氢-13H-16-氧杂-4b,8a,14-三氮杂-5,8-亚甲桥二苯并[b,h]环辛[jkl]环戊[e]-as-茚并苯并环戊酮 |
英文名称 |
(5S,6S,8R)-6-Hydroxy-6-(hydroxymethyl)-5-methyl-5,6,7,8,14,15-hexahydro-13H-16-oxa-4b,8a,14-triaza-5,8-methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacen-13-one |
别名 |
SPM-924 | (5S,6S,8R)-6-hydroxy-6-(hydroxymethyl)-5-methyl-7,8,14,15-tetrahydro-5H-16-oxa-4b,8a,14-triaza-5,8-methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacen-13(6H)-one | CEP-701 | KT-5555 |
标准英文名 |
(5S,6S,8R)-6-hydroxy-6-(hydroxymethyl)-5-methyl-5,6,7,8,14,15-hexahydro-13H-16-oxa-4b,8a,14-triaza-5,8-methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacen-13-one |
MDL No. |
MFCD09840836 |
分子式 |
C26H21N3O4 |
分子量 |
439.47
|
精确分子量 |
439.15
|
SMILES |
O=C1NCC(C2=C3N([C@]4(C)[C@](CO)(O)C[C@@]5([H])O4)C6=CC=CC=C62)=C1C7=C3N5C8=CC=CC=C78 |
标准SMILES |
C[C@]12O[C@H](C[C@]1(O)CO)N1C3C4=C(C5CNC(=O)C=5C=3C3=CC=CC=C13)C1=CC=CC=C1N24 |
用途 |
Lestaurtinib is a multi-targeted indolocarbazole derivative that effectively inhibits FLT3 autophosphorylation in vitro and has demonstrated therapeutic efficacy in the treatment of diseases such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and acute lymphoblastic leukemia (ALL). It is an ATP-competitive multi-kinase inhibitor with potent activity against the Trk family of receptor tyrosine kinases. Lestaurtinib is currently under investigation in multiple advanced clinical trials for its use in both adult and pediatric leukemia. |
InChIKey |
UIARLYUEJFELEN-LROUJFHJSA-N |